Re: Kimmo Kettunen, Peter J. Boström, Tarja Lamminen, et al. Personalized Drug Sensitivity Screening for Bladder Cancer Using Conditionally Reprogrammed Patient-derived Cells. Eur Urol 2019;76:430-4: Can Patient-derived Cancer Models Change the Costliest Cancer Type?
1 Departments of Pathology and Oncology, Center for Cell Reprogramming, Lombardi Comprehensive Cancer, Georgetown University, Washington, DC, USA. Electronic address: xuefeng.liu@georgetown.edu.